ROVI’s ESG (Environmental, Social and Governance) criteria were evaluated by Sustainalytics, a leading company in the evaluation of Corporate Social Responsibility and Corporate Governance at world level, having achieved an ESG risk rating of 18.4 points, which places the company in a low risk position (between 10 and 20 points). This rating improves by 3.4 points on the previous year (21.8 points), when the company reached a medium risk position (between 20 and 30 points).
In this classification, ROVI obtained the second best rating out of 432 companies evaluated in the pharmaceutical industry category and 17th out of a total of 896 companies in the sector, which includes biotechnology, pharmaceutical laboratories and healthcare equipment companies.
You can consult ROVI’s evaluation at THIS LINK


